Compare Vivmark Residential Common Shares of Beneficial Interest (VMRK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vivmark Residential Common Shares of Beneficial Interest vs State Street SPDR S&P Biotech ETF — how do they compare? Vivmark Residential Common Shares of Beneficial Interest trades at $61.01 (market cap $46.41B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 4.6× State Street SPDR S&P Biotech ETF's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays a 4.68% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vivmark Residential Common Shares of Beneficial Interest for 1 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VMRK | XBI | |
|---|---|---|
Market Cap | $46.41B | $10.11B |
Volume | 6,584,008 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $70.15 | $169.55 |
52-Week Low | $57.98 | $104.99 |
Typical Hold Time | 1 Days | 37 Days |
Enterprise Value | $55.52B | — |
Dividend Yield | 4.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
